The Department of Emergency Medicine has been awarded two National Institutes of Health grants totaling over $5 million to improve patient care. They include an effort to better evaluate pediatric trauma patients and another to identify effective treatments early in emergency care.
Two new studies from researchers at Fred Hutchinson Cancer Center in Seattle reveal how bacteria infiltrate tumors and could be helping tumors progress and spread and suggest a link between oral health and cancer, as microbes in the mouth are associated with cancers elsewhere in the body. The two papers – one published Nov. 15 in Cell Reports and the other published Nov. 16 in Nature – focus on an oral bacterium called Fusobacterium nucleatum, which has been linked to colorectal cancer.
Rutgers Cancer Institute of New Jersey social worker shares how everyone can use mindfulness to cope with cancer during the holidays.
National Comprehensive Cancer Network and the Latin American and Caribbean Society of Medical Oncology collaborate to address policy and practice solutions to increase equitable access for breast cancer care, starting in Argentina and then expanding more broadly.
UC Davis Health and AI software company Illuminate have developed a centralized abdominal aortic aneurysm surveillance program using artificial intelligence software. The effort identifies at-risk abdominal aortic aneurysm patients who may have been ‘lost-to-follow-up’ either due to COVID-19 or other factors.
Four recipients of the Lubin Family Foundation Scholar award are announced -- these scholars are among the most promising physician-scientists and are on track to becoming the next generation of leaders in cancer research.
New research from Yale Cancer Center identified that two simple biomarkers, immune cells and estrogen receptor levels, could differentiate which young women with ER+ breast cancer need chemotherapy to improve their survival, and which only need a monthly injection to suppress ovarian function.The findings were recently published in npjBreast, Nature Partner Journals.
MD Anderson and Exscientia today announced a strategic collaboration to align the drug development expertise of MD Anderson with the patient-centric AI capabilities of Exscientia to advance new targeted cancer therapies.
Eyal Gottlieb, Ph.D., has been named MD Anderson's vice president for Research. Gottlieb, an accomplished scientist and leader, will join the institution in January to uphold and expand the institution’s research excellence.
A team of researchers at The University of Texas MD Anderson Center has developed a nanotechnology platform that can change the way the immune system sees solid tumor cells, making them more receptive to immunotherapy. The preclinical findings suggest this adaptable immune conversion approach has the potential for broad application across many cancer types.
The National Comprehensive Cancer Network’s Oncology Research Program selects projects focused on improving patient care and outcomes in locally advanced or metastatic bladder cancer.
A study in JNCCN, led by researchers at Duke University School of Medicine, found that Non-Hispanic Black patients were less likely to receive guideline-appropriate treatment for ovarian cancer compared to Non-Hispanic White patients, even after adjusting for healthcare access issues.
This special edition features upcoming presentations by MD Anderson researchers at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, including immunotherapy advances in human papillomavirus (HPV)-positive head and neck cancers, microbiome signatures linked with specialized immune-cell clusters, and promising early activity from novel immunotherapy drugs in advanced melanoma and colorectal cancer.
Marvel Studios’ movie, “Black Panther: Wakanda Forever,” is the highly anticipated sequel to “Black Panther,” hitting theaters on November 11th. It will premiere without “Black Panther” star Chadwick Boseman, who passed away in 2020 from colorectal cancer at the age of 43. Boseman’s death was a stark reminder of the alarming rise in colorectal cancer in patients younger than 50, as well as the higher incidence and mortality of this disease in the non-Hispanic Black population.
A former fellow at the UNM Comprehensive Cancer Center, Dr. Shashank Cingam comes back to New Mexico to Treat blood cancers.
Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment over three weeks instead of five, with comparable tumor control and no increased risk of major complications in wound healing, according to researchers at The University of Texas MD Anderson Cancer Center.
20240208171546.png&width=400&height=400)
Stigma can have profound and lasting effects, and studies have shown that people living with lung cancer may encounter challenges in receiving the support they need from their social network and healthcare providers. Memorial Sloan Kettering Cancer Center (MSK) is committed to helping eliminate the stigmas associated with a lung cancer diagnosis and is working to raise awareness in collaboration with other national organizations.
Thousands are expected at MD Anderson’s Boot Walk to End Cancer® on Saturday, Nov. 5, as The University of Texas MD Anderson Cancer Center prepares for the in-person return of the seventh annual event in the Texas Medical Center.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
Patients with cancer and a weakened immune system who are treated with immunotherapies tend to fare far worse from COVID-19 than those who haven't received such therapies in the three months before their COVID diagnosis, show findings in a new study by researchers at Dana-Farber Cancer Institute, and across the U.S., Canada, and Mexico. Researchers found worse outcomes in both the disease itself as well as the fierce immune response that sometimes accompanies it.
A targeted therapy for children with high-risk Hodgkin lymphoma significantly reduced relapse rates, a large multicenter clinical trial conducted by the Children’s Oncology Group shows. The study results have been reported in the New England Journal of Medicine.
SEATTLE — November 2, 2022 — Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news.
Ceremony Marks the Completion of the Steel Construction Phase
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco (UCSF) has discovered the underlying cause of gender differences in immunotherapy-associated myocarditis after immune checkpoint inhibitor (ICI) treatment. Their findings point to possible treatment strategies for this side effect, which disproportionately affects female patients.
United States-based National Comprehensive Cancer Network enters strategic cooperation agreement with Chinese medical information website to publish and translate evidence-based expert consensus guidelines for cancer care; now available at nccnchina.org.cn.
Memorial Sloan Kettering Cancer Center (MSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (Cotellic®) for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms (HN). These diseases include Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis. Cobimetinib is an oral inhibitor of MEK1 and MEK2, currently approved to treat melanoma.
November is National Family Caregivers Month
Roswell Park Comprehensive Cancer Center and Moffitt Cancer Center have partnered with more than 50 other cancer organizations to issue a call to action urging individuals, providers and insurers to increase access to and utilization of low-dose CT scans for those at high risk for lung cancer.
Although some pancreas cysts are benign, the majority are pre-cancerous and are the most common identifiable precursor to pancreatic cancer.
Joint call to action urges individuals, providers and insurers to increase access to and utilization of low-dose CT screening for those at high risk for lung cancer.
Haejin In, MD, MPH, MBA, FACS, FSSO, is chief diversity officer, associate director for Diversity, Equity and Inclusion, and surgical oncologist at Rutgers Cancer Institute of New Jersey, shares the facts, the warning signs and concerns for the disease in Asian Americans.
UC Davis Health has again been recognized in the 2022 Digital Health “Most Wired” program from the College of Healthcare Information Management Executives (CHIME). The health system earned a certified level 10, the highest level, on both the acute and ambulatory care surveys.
According to the American Lung Association, Black Americans, Latinos, Asian Americans or Pacific Islanders and Indigenous people who are diagnosed with lung cancer face worse outcomes compared to white Americans because they are less likely to be diagnosed early. Rutgers Cancer Institute expert shares how these disparities are being addressed and where to find cancer screening resources.
According to the 2021-2023 edition of the American Cancer Society’s Cancer Facts and Figures for Hispanic/Latino People, about 6,000 Hispanic men and 5,800 Hispanic women are expected to be diagnosed with cancer of the lung and 3,200 Hispanic men and 2,300 Hispanic women are expected to die from the disease this year. Expert from Rutgers Cancer Institute shares what the Hispanic community needs to know about the disease.
A Ludwig Cancer Research study has developed a novel nanotechnology that triggers potent therapeutic anti-tumor immune responses and demonstrated its efficacy in mouse models of multiple cancers.
Colorectal cancer is one of the most common cancers. Its treatment is mainly based on chemotherapy.
The University of Texas MD Anderson Cancer Center today announced that the Timken Foundation of Canton, Ohio, has made a $5 million commitment to support the James P. Allison Institute at MD Anderson. The gift will support the recruitment of top minds from around the world to help realize the Allison Institute’s goals. By establishing a diverse and inclusive environment of scientists from many fields, the Allison Institute will drive exceptional research that integrates immunobiology across disciplines to develop a comprehensive understanding of the immune system.
In recognition of her trailblazing work in uncovering the mechanisms of the p53 tumor suppressor, Guillermina “Gigi” Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been selected to receive the 2022 Award for Distinguished Research in the Biomedical Sciences by the Association of American Medical Colleges (AAMC).
New research from Yale Cancer Center reveals for the first time ever a differential clinical response to pembrolizumab in Lynch-like (mutated) vs methylated microsatellite instability-high (MSI-H) uterine cancer patients, increasing our understanding about the proportion of patients that derive benefit from immune checkpoint blockade.
Free online event for cancer patients and caregivers featuring immunotherapy experts and patient advocates taking place Nov. 11-12, 2022.
The American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR) have issued an updated policy, regarding the use of electronic nicotine delivery systems (ENDS). Roy S. Herbst, MD, PhD, is corresponding author on the statement published today in both Clinical Cancer Research and the Journal of Clinical Oncology.
Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of patients in a Phase II study, researchers from The University of Texas MD Anderson Cancer Center reported in Nature.
Patients with early-stage breast cancer who had a pathologic complete response (pCR) to neoadjuvant chemotherapy may be able to skip surgery and receive standard radiation treatment with a low chance of disease recurrence, according to a new study from researchers at The University of Texas MD Anderson Cancer Center. The Phase II trial results, published today in Lancet Oncology, evaluated the likelihood of breast cancer returning in patients who are in complete remission after receiving chemotherapy and radiation without surgery.
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were presented today at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting.
Using a novel response-adapted ultra-low dose radiation therapy strategy, MD Anderson researchers observed a 90% complete response rate in patients with orbital indolent B-cell lymphoma. The results were presented today at the 2022 ASTRO Annual Meeting.
A new study may prompt medical experts to rethink when to start mammograms for women who have a mother, sister or daughter diagnosed with breast cancer.
In a study published today in JAMA Oncology, researchers at Yale Cancer Center in collaboration with researchers from Flatiron Health, Inc., revealed that despite recommendations, aggressive cancer care at the end-of-life persists and there has been a substantial transition from the use of chemotherapy to immunotherapy.
MD Anderson's James P. Allison institute today announced the establishment of its internal advisory council to provide scientific input and to align the work of the institute with the broader MD Anderson research enterprise.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right